[go: up one dir, main page]

NO20082097L - Farmasoytiske sammensetninger - Google Patents

Farmasoytiske sammensetninger

Info

Publication number
NO20082097L
NO20082097L NO20082097A NO20082097A NO20082097L NO 20082097 L NO20082097 L NO 20082097L NO 20082097 A NO20082097 A NO 20082097A NO 20082097 A NO20082097 A NO 20082097A NO 20082097 L NO20082097 L NO 20082097L
Authority
NO
Norway
Prior art keywords
pharmaceutical compositions
azd2171
pharmaceutically acceptable
acceptable salt
lactose
Prior art date
Application number
NO20082097A
Other languages
English (en)
Inventor
David Bradley Brook Simpson
Julie Kay Cahill
Sebastien Richer
Daren James Cumberbatch
David John Holt
Elizabeth Anne Swain
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20082097L publication Critical patent/NO20082097L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Farmasøytiske preparater omfattende AZD2171 eller et farmasøytisk akseptabelt salt derav, inkludert farmasøytiske preparater omfattende AZD2171 eller et farmasøytisk akseptabelt salt og et plastisk fyllmiddel med et høyt overflateareal, som ikke er laktose.
NO20082097A 2005-11-23 2008-05-06 Farmasoytiske sammensetninger NO20082097L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0523810.0A GB0523810D0 (en) 2005-11-23 2005-11-23 Pharmaceutical compositions
PCT/GB2006/004320 WO2007060402A1 (en) 2005-11-23 2006-11-21 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
NO20082097L true NO20082097L (no) 2008-08-18

Family

ID=35601030

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082097A NO20082097L (no) 2005-11-23 2008-05-06 Farmasoytiske sammensetninger

Country Status (17)

Country Link
US (1) US20090028943A1 (no)
EP (2) EP1954247A1 (no)
JP (1) JP2009516726A (no)
KR (1) KR20080070056A (no)
CN (2) CN101312715B (no)
AR (1) AR057928A1 (no)
AU (1) AU2006318946A1 (no)
BR (1) BRPI0618906A2 (no)
CA (1) CA2628917A1 (no)
EC (1) ECSP088555A (no)
GB (1) GB0523810D0 (no)
NO (1) NO20082097L (no)
RU (1) RU2008125197A (no)
TW (1) TW200735875A (no)
UY (1) UY29952A1 (no)
WO (1) WO2007060402A1 (no)
ZA (1) ZA200804103B (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200500745T2 (tr) 1999-02-10 2005-05-23 Astrazeneca Ab Damar gelişimi inhibitörleri olarak kuinazolin türevleri.
GB0330002D0 (en) * 2003-12-24 2004-01-28 Astrazeneca Ab Quinazoline derivatives
RU2519768C2 (ru) * 2008-06-20 2014-06-20 Мерк Патент Гмбх Поддающаяся прямому прессованию и быстро распадающаяся матрица таблетки
WO2010005527A1 (en) 2008-06-30 2010-01-14 Angioblast Systems, Inc. Treatment of eye diseases and excessive neovascularization using a combined therapy
TW201129386A (en) 2009-11-05 2011-09-01 Fmc Corp Microcrystalline cellulose and calcium phosphate compositions useful as pharmaceutical excipients
WO2013059740A1 (en) 2011-10-21 2013-04-25 Foundation Medicine, Inc. Novel alk and ntrk1 fusion molecules and uses thereof
WO2014071419A2 (en) 2012-11-05 2014-05-08 Foundation Medicine, Inc. Novel fusion molecules and uses thereof
HK1214830A1 (zh) 2012-11-05 2016-08-05 Foundation Medicine, Inc. 新型ntrk1融合分子及其应用
WO2014113729A2 (en) 2013-01-18 2014-07-24 Foundation Mecicine, Inc. Methods of treating cholangiocarcinoma
DK3003284T3 (da) 2013-06-06 2020-03-30 Fibrogen Inc Farmaceutiske formuleringer af en hif-hydroxylase-inhibitor
EP3414330A4 (en) 2016-02-08 2019-07-03 Vitrisa Therapeutics, Inc. COMPOSITIONS WITH IMPROVED INTRAVITREAL HALF TIME AND USES THEREOF
IL297218A (en) * 2020-04-24 2022-12-01 Astrazeneca Ab Pharmaceutical formulations
CN115400136B (zh) * 2022-07-22 2023-10-03 江苏亚邦爱普森药业有限公司 一种克拉霉素固体制剂及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200500745T2 (tr) 1999-02-10 2005-05-23 Astrazeneca Ab Damar gelişimi inhibitörleri olarak kuinazolin türevleri.
ATE371439T1 (de) * 2000-07-27 2007-09-15 Roquette Freres Granulat bestehend aus stärke und laktose
SE0101329D0 (sv) * 2001-04-12 2001-04-12 Astrazeneca Ab Pharmaceutical formulation
CA2363528A1 (en) * 2001-11-19 2003-05-19 Merck Patent Gesellschaft Mit Beschraenkter Haftung Immediate release tablet containing naproxen sodium
BR0307151A (pt) * 2002-02-01 2004-12-07 Astrazeneca Ab Composto ou um sal do mesmo, processo para a preparação do mesmo, composição farmacêutica, uso do composto ou de um seu sal, método para produzir um efeito antiangiogênico e/ou redutor da permeabilidade vascular em um animal de sangue quente, como um ser humano, que necessita de um tratamento do tipo referido, e, processos para a preparação de 5-bromo-7- azaindol, e para a produção de 5-metóxi-7-azaindol
CA2488499C (en) * 2002-06-10 2013-03-19 Elan Pharma International Ltd. Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives ("statins"),combinations thereof as well as manufacturing of these pharmaceutical compositions
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
GB0330002D0 (en) * 2003-12-24 2004-01-28 Astrazeneca Ab Quinazoline derivatives

Also Published As

Publication number Publication date
JP2009516726A (ja) 2009-04-23
RU2008125197A (ru) 2009-12-27
CN101312715B (zh) 2011-12-14
BRPI0618906A2 (pt) 2013-01-08
TW200735875A (en) 2007-10-01
AR057928A1 (es) 2007-12-26
CN102327267A (zh) 2012-01-25
CN101312715A (zh) 2008-11-26
ECSP088555A (es) 2008-07-30
UY29952A1 (es) 2007-06-29
US20090028943A1 (en) 2009-01-29
KR20080070056A (ko) 2008-07-29
EP2283828A1 (en) 2011-02-16
EP1954247A1 (en) 2008-08-13
CA2628917A1 (en) 2007-05-31
ZA200804103B (en) 2009-10-28
WO2007060402A1 (en) 2007-05-31
AU2006318946A1 (en) 2007-05-31
GB0523810D0 (en) 2006-01-04

Similar Documents

Publication Publication Date Title
NO20082097L (no) Farmasoytiske sammensetninger
NO20082376L (no) Farmasoytiske sammensetninger
DK2051975T3 (da) Substituerede prolinamider, fremstilling deraf og anvendelse deraf som lægemiddel.
DK3984528T3 (da) Farmaceutiske sammensætninger, som omfatter nilotinib
DK2010190T3 (da) Farmaceutisk opløsningsformulering til tryksatte, dosisregulerede inhalatorer
BRPI0809366A8 (pt) polipeptídeos interligados
NO343776B1 (no) Forbindelse som modulerer farmakokinetikkegenskaper til terapeutika, dens anvendelse i terapi og farmasøytisk sammensetning derav.
NO20091395L (no) Nye tiofenderivater
NO20076613L (no) Farmasoytiske formuleringer og anvendelse derav
DK1940243T3 (da) Kostfiberformulering og fremgangsmåde til indgivelse
BRPI0815894A2 (pt) Composição farmacêutica, uso da mesma, e, sais farmaceuticamente aceitáveis de um composto.
IL195813A0 (en) Substituted aminopyrazolopyridines and salts thereof, their preparations and pharmaceutical compositions comprising them
BRPI0818483A2 (pt) Método para preparar uma composição farmacêutica, composição farmacêutica, e, uso da mesma.
EA201070689A1 (ru) Композиция для личного ухода
BRPI0807078A2 (pt) Composto, e, formulação farmacêutica
DE602007014036D1 (de) 12-aryl-prostaglandin-analoga
GT200800107A (es) Formulaciones orales que comprenden tigeciclina
NO20092690L (no) Aminderivater og deres anvendelse i beta-2-adrenoreseptormedierte sykdommer
NO20053119D0 (no) Farmasoytiske sarmmensetninger med fentanyl for intranasal administrasjon.
BRPI0807001A2 (pt) Formulação farmacêutica, e, método para preparação de uma formulação farmacêutica.
ZA200900237B (en) Substituted aminopyrazolopyridines and salts thereof, their preparations and pharmaceutical compositions comprising them
EA200900958A1 (ru) Препарат невирапина пролонгированного высвобождения
EA200600953A1 (ru) Дозированные формы торсемида пролонгированного высвобождения
DK1729819T3 (da) Indgivelsesanordning til lægemidler, som er röntgenstråle-synlige
ITMI20041245A1 (it) Composizioni farmaceutiche iniettabnili comprendenti diclofenac sodico e b-ciclodestrina

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application